XML 52 R16.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stockholders' Equity
 9 Months Ended
Sep. 27, 2013
Stockholders' Equity

Note 11—Stockholders’ Equity

On September 25, 2013, the Company completed a public offering of 3,800,000 share of its common stock at $21.00 per share. The Company recognized proceeds of approximately $75,060 after deducting underwriting fees and commissions and estimated offering expenses. The Company utilized approximately $12,500 of the net proceeds from the offering to repay outstanding borrowings under the Revolving Credit Facility. The remaining net proceeds are being held by the Company for general corporate purposes.

During the 39 weeks ended September 27, 2013, the Company granted 249,760 restricted stock awards (“RSAs”) to its employees and independent outside directors at a weighted average grant date fair value of $16.30 each. Of these awards, 183,700 were performance-based grants. The Company recognized no expense on the performance-based grants during the 39 weeks ended September 27, 2013 as the Company is not on track to achieve the performance targets. The remaining awards were time-based grants which will vest between one and four years. During the 13 and 39 weeks ended September 27, 2013, the Company recognized expense totaling $114 and $245, respectively, on these time-based RSAs.

During the 13 and 39 weeks ended September 27, 2013, the Company recognized $189 and $647, respectively, of expense for RSAs issued in prior years.

At September 27, 2013, the Company had 403,744 of unvested RSAs outstanding. At September 27, 2013, the total unrecognized compensation cost for these unvested RSAs was $6,284, and the weighted-average remaining useful life was approximately 18 months. Of this total, $3,123 related to RSAs with time-based vesting provisions and $3,161 related to RSAs with performance-based vesting provisions. At September 27, 2013, the weighted-average remaining useful lives were approximately 21 months for time-based vesting RSAs and 14 months for the performance-based vesting RSAs. No compensation expense related to the Company’s RSAs has been capitalized.

As of September 27, 2013, there were 1,118,648 shares available for grant under the Company’s 2011 Omnibus Equity Incentive Plan.